Who is sponsoring NCT06889649?

NCT06889649 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT06889649?

Interventions in NCT06889649: Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI).

What condition does NCT06889649 study?

NCT06889649 studies Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic.

Is NCT06889649 still recruiting?

NCT06889649 is currently recruiting now. Last updated 21 March 2025.

Last reviewed 2025-03-21 · How we verify

NCT06889649

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Recruiting now Phase 2 Last updated 21 March 2025

What this trial tests

Phase 2 trial testing Stereotactic Ablative Body Radiotherapy (SABR) in Radiation Therapy in 30 participants. Currently enrolling.

Timeline

1 January 2019

Primary endpoint
28 February 2027

20 February 2028

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2019
Primary completion	28 February 2027
Estimated completion	20 February 2028
Sites	1 location across China

Drugs / interventions tested

Stereotactic Ablative Body Radiotherapy (SABR)
TORIPALIMAB INJECTION(JS001 ) — full drug profile →
Axitinib (VEGF-TKI) — full drug profile →

Conditions studied

Radiation Therapy — all drugs for Radiation Therapy →
Targeted Therapy — all drugs for Targeted Therapy →
Immunotherapy — all drugs for Immunotherapy →
Renal Cancer Metastatic — all drugs for Renal Cancer Metastatic →

Sponsor

Peking University First Hospital

Who can join

Adults 18 to 80, any sex, with Radiation Therapy or Targeted Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the immunotherapy Toripalimab in patients with recurrent metastatic renal cell carcinoma (RCC). Patients will receive a treatment regimen consisting of Axitinib, Toripalimab, and comprehensive multi-lesion SABR. The primary endpoint is Progression-Free Survival 1 (PFS1), and secondary endpoints include Progression-Free Survival 2 (PFS2), Overall Survival (OS), Local Control (LC), Objective Response Rate (ORR), and Disease Control Rate (DCR). Adverse events will be monitored according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0). The aim of this study is to explore a potentially more effective treatment combination for recurrent metastatic RCC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?
Dong Z, Li S, Li M, Fan M, et al · · 2025 · cited 1× · PMID 41281942 · DOI 10.20517/cdr.2025.157
Efficacy and safety of SABR/partial-SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial.
Hu K, Ma MW, Gao XS, Li HZ, et al · · 2025 · PMID 40503038 · DOI 10.3892/ol.2025.15122

Verify or expand the search:

Other trials of Stereotactic Ablative Body Radiotherapy (SABR)

Trials testing the same drug.

NCT04915417 — Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma · NA · unknown

Other recruiting trials for Radiation Therapy

Currently open trials in the same condition.

NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
NCT06546592 — Locally Optimised Contouring With AI Technology for Radiotherapy · NA · recruiting
NCT06746428 — Activity Coaching During Pelvic Radiation Therapy · NA · recruiting
NCT06946420 — SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy · Phase 3 · active not recruiting
NCT06579248 — Intraoral Hypothermia Device for Preserving Taste During Radiation · EARLY_PHASE1 · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06889649 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 21 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06889649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing